Next Article in Journal
Breakdown of Phosphatidylserine Asymmetry Following Treatment of Erythrocytes with Lumefantrine
Next Article in Special Issue
Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects
Previous Article in Journal
Botulinum Neurotoxin A Complex Recognizes Host Carbohydrates through Its Hemagglutinin Component
Previous Article in Special Issue
Impact of Antidepressants on Cytokine Production of Depressed Patients in Vitro
Toxins 2014, 6(2), 636-649; doi:10.3390/toxins6020636
Article

Antitumor Cell-Complex Vaccines Employing Genetically Modified Tumor Cells and Fibroblasts

1
, 1,2,* , 1
, 3
, 4
, 5
 and 1,6,*
Received: 30 November 2013; in revised form: 28 January 2014 / Accepted: 5 February 2014 / Published: 19 February 2014
(This article belongs to the collection Toxicity and Therapeutic Interventions in the Immune System)
View Full-Text   |   Download PDF [338 KB, updated 20 February 2014; original version uploaded 19 February 2014]   |   Browse Figures
Abstract: The present study evaluates the immune response mediated by vaccination with cell complexes composed of irradiated B16 tumor cells and mouse fibroblasts genetically modified to produce GM-CSF. The animals were vaccinated with free B16 cells or cell complexes. We employed two gene plasmid constructions: one high producer (pMok) and a low producer (p2F). Tumor transplant was performed by injection of B16 tumor cells. Plasma levels of total IgG and its subtypes were measured by ELISA. Tumor volumes were measured and survival curves were obtained. The study resulted in a cell complex vaccine able to stimulate the immune system to produce specific anti-tumor membrane proteins (TMP) IgG. In the groups vaccinated with cells transfected with the low producer plasmid, IgG production was higher when we used free B16 cell rather than cell complexes. Nonspecific autoimmune response caused by cell complex was not greater than that induced by the tumor cells alone. Groups vaccinated with B16 transfected with low producer plasmid reached a tumor growth delay of 92% (p ≤ 0.01). When vaccinated with cell complex, the best group was that transfected with high producer plasmid, reaching a tumor growth inhibition of 56% (p ≤ 0.05). Significant survival (40%) was only observed in the groups vaccinated with free transfected B16 cells.
Keywords: cancer vaccines; gene therapy; non-viral; bystander cells; cell complexes cancer vaccines; gene therapy; non-viral; bystander cells; cell complexes
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Miguel, A.; Herrero, M.J.; Sendra, L.; Botella, R.; Diaz, A.; Algás, R.; Aliño, S.F. Antitumor Cell-Complex Vaccines Employing Genetically Modified Tumor Cells and Fibroblasts. Toxins 2014, 6, 636-649.

AMA Style

Miguel A, Herrero MJ, Sendra L, Botella R, Diaz A, Algás R, Aliño SF. Antitumor Cell-Complex Vaccines Employing Genetically Modified Tumor Cells and Fibroblasts. Toxins. 2014; 6(2):636-649.

Chicago/Turabian Style

Miguel, Antonio; Herrero, María J.; Sendra, Luis; Botella, Rafael; Diaz, Ana; Algás, Rosa; Aliño, Salvador F. 2014. "Antitumor Cell-Complex Vaccines Employing Genetically Modified Tumor Cells and Fibroblasts." Toxins 6, no. 2: 636-649.


Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert